Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Director Barry Quart Sells 12,528 Shares

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Director Barry Quart sold 12,528 shares of the stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $45.27, for a total value of $567,142.56. Following the sale, the director owned 12,546 shares in the company, valued at $567,957.42. The trade was a 49.96% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Kiniksa Pharmaceuticals International Stock Down 3.2%

KNSA stock opened at $43.52 on Thursday. Kiniksa Pharmaceuticals International, plc has a twelve month low of $18.12 and a twelve month high of $45.50. The stock has a market capitalization of $3.30 billion, a price-to-earnings ratio of 96.71 and a beta of 0.06. The firm’s fifty day simple moving average is $41.80 and its two-hundred day simple moving average is $38.09.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its quarterly earnings results on Tuesday, October 28th. The company reported $0.23 EPS for the quarter, missing the consensus estimate of $0.31 by ($0.08). The firm had revenue of $180.86 million for the quarter, compared to the consensus estimate of $166.64 million. Kiniksa Pharmaceuticals International had a net margin of 6.01% and a return on equity of 7.46%. The business’s revenue for the quarter was up 61.2% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.18) earnings per share. As a group, equities research analysts expect that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on KNSA. Citigroup raised their price target on shares of Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the stock a “buy” rating in a research note on Friday, October 17th. Zacks Research cut Kiniksa Pharmaceuticals International from a “hold” rating to a “strong sell” rating in a research note on Tuesday, January 13th. Wedbush raised their target price on shares of Kiniksa Pharmaceuticals International from $48.00 to $50.00 and gave the company an “outperform” rating in a research note on Tuesday, January 13th. The Goldman Sachs Group boosted their price target on Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a report on Thursday, January 22nd. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Kiniksa Pharmaceuticals International currently has a consensus rating of “Moderate Buy” and an average target price of $52.33.

Institutional Trading of Kiniksa Pharmaceuticals International

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. USA Financial Formulas acquired a new stake in shares of Kiniksa Pharmaceuticals International during the 3rd quarter valued at about $32,000. EverSource Wealth Advisors LLC grew its holdings in Kiniksa Pharmaceuticals International by 140.4% in the second quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $25,000 after purchasing an additional 532 shares during the period. Quarry LP purchased a new stake in shares of Kiniksa Pharmaceuticals International in the third quarter valued at approximately $44,000. Osaic Holdings Inc. acquired a new position in shares of Kiniksa Pharmaceuticals International during the 2nd quarter worth approximately $31,000. Finally, Farther Finance Advisors LLC lifted its position in shares of Kiniksa Pharmaceuticals International by 582.4% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,358 shares of the company’s stock valued at $53,000 after buying an additional 1,159 shares in the last quarter. Institutional investors and hedge funds own 53.95% of the company’s stock.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.